12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

TTP399: Phase IIa data

TransTech said data from a Phase IIa trial in 128 Type II diabetics on stable doses of metformin showed that TTP399 significantly reduced HbA1c from baseline at week 6 vs. placebo (placebo-corrected reduction of 0.53%, p<0.001). In patients with baseline HbA1c <=7.5%, TTP399 led to target HbA1c levels of <=7% in 100% of...

Read the full 241 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >